David Alan Campbell Sells 25,000 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 25,000 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $51.60, for a total transaction of $1,290,000.00. Following the sale, the chief executive officer now owns 257,054 shares of the company’s stock, valued at $13,263,986.40. This trade represents a 8.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

David Alan Campbell also recently made the following trade(s):

• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $53.54, for a total value of $1,338,500.00.
• On Friday, September 27th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $46.31, for a total value of $1,157,750.00.

Janux Therapeutics Price Performance

NASDAQ JANX opened at $46.39 on Friday. The business has a 50 day moving average price of $49.98 and a 200 day moving average price of $45.83. The company has a market capitalization of $2.43 billion, a P/E ratio of -39.65 and a beta of 3.52. Janux Therapeutics, Inc. has a 1-year low of $7.79 and a 1-year high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The firm had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics’s revenue for the quarter was down 82.6% compared to the same quarter last year. On average, research analysts expect that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $100.00 price objective on shares of Janux Therapeutics in a research report on Thursday, November 7th. UBS Group assumed coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price on the stock. Leerink Partners began coverage on shares of Janux Therapeutics in a report on Friday, November 22nd. They set an “outperform” rating and a $79.00 price target for the company. Wedbush restated an “outperform” rating and issued a $74.00 price objective on shares of Janux Therapeutics in a research report on Thursday, August 8th. Finally, Stifel Nicolaus initiated coverage on Janux Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Janux Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $67.70.

Institutional Trading of Janux Therapeutics

Large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Janux Therapeutics by 38.6% in the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after buying an additional 378,477 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of Janux Therapeutics in the first quarter valued at $739,000. Artal Group S.A. acquired a new stake in shares of Janux Therapeutics during the first quarter valued at $1,882,000. Virtu Financial LLC acquired a new stake in shares of Janux Therapeutics during the first quarter valued at $609,000. Finally, DNB Asset Management AS purchased a new stake in Janux Therapeutics during the 2nd quarter worth about $221,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.